LINKSTER THERAPEUTICS - Key Persons

Job Titles:

• Chief Scientific Officer
• Co - Founder
• Founder

Iwan Zimmermann is one of the founders and Chief Scientific Officer of Linkster Therapeutics. Iwan has over 12 years of experience with single domain antibodies and the biology of ion channels and transporters. Prior to co-founding Linkster Therapeutics, Iwan conducted research as platform leader for smart library design and antibody discovery at the University of Zurich. He co-invented the Flycode and Sybody technologies and proved successful as a team player and project leader in a large number of collaborative early drug portfolio projects with pharmaceutical companies worldwide. Iwan obtained his master and PhD degrees in Biochemistry at the University of Zurich. In 2018, he was awarded the UZH Bioentrepreneur fellowship program.

Job Titles:

• Chief Executive Officer
• Co - Founder
• Founder

Roger Dawson is one of the founders and Chief Executive Officer of Linkster Therapeutics. Roger has over 11 years of experience in research and drug development working at F.Hoffmann-La Roche. He contributed to the advancement of drug molecules as team player and leader of international and cross-functional teams. Inter alia, Roger served as head of translational protein science, project leader and implemented Roche's ‘membrane protein platform'. As a renowned drug discovery expert, he lead-authored numerous publications in the GPCR, ion channel and transporter field. Roger holds a masters degree in Chemistry from the TUM and obtained his PhD in Biology at the ETH Zurich. He was awarded Roche's RPF fellowship and the Swiss Federal Center of Technology and Innovation (Innosuisse) program.